CORT vs SYRE: stock comparison and AI forecast
Corcept Therapeutics Inc (CORT) and Spyre Therapeutics, Inc. (SYRE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CORT Corcept Therapeutics Inc
- Market Cap
- $8.86B
- P/E Ratio
- 49.1x
- Size
- mid-cap
- AI Forecast
SYRE Spyre Therapeutics, Inc.
- Market Cap
- $8.75B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CORT and SYRE have similar market capitalizations ($8.86B and $8.75B).
- CORT carries 0.24 times debt per unit of equity, against 0.05 times for SYRE.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CORT | SYRE |
|---|---|---|
| Market Cap | $8.86B | $8.75B |
| P/E Ratio | 49.06x | – |
| P/B Ratio | 10.62x | 8.32x |
| EPS | $1.67 | $-2.19 |
| Book Value/Share | $7.71 | $11.93 |
| Revenue/Share | $8.91 | – |
| FCF/Share | $1.80 | – |
Profitability & Margins
| Metric | CORT | SYRE |
|---|---|---|
| ROE | 19.5% | -25.1% |
| ROA | 15.7% | -24.0% |
| ROIC | 12.9% | -23.6% |
| Gross Margin | 98.5% | – |
| Operating Margin | 11.5% | – |
| Net Margin | 16.8% | – |
| EBT Margin | 13.5% | – |
| Tax Rate | -23.7% | 0.0% |
Financial Health
| Metric | CORT | SYRE |
|---|---|---|
| Current Ratio | 3.00x | 27.40x |
| Quick Ratio | 2.94x | – |
| D/E Ratio | 0.24x | 0.05x |
| Financial Leverage | 1.24x | 1.05x |
| Working Capital | $356M | $1.06B |
Cash Flow
| Metric | CORT | SYRE |
|---|---|---|
| Operating Cash Flow | $198M | -$249M |
| Free Cash Flow | $195M | – |
| Capital Spending | -$3M | – |
| OCF Growth YoY | 21.6% | – |
| FCF Growth YoY | 19.7% | – |
| FCF/Sales | 20.2% | – |
| CapEx/Sales | 0.4% | – |
Operational Efficiency
| Metric | CORT | SYRE |
|---|---|---|
| Asset Turnover | 0.93x | – |
| Receivables Turnover | 8.7x | – |
| Inventory Turnover | 1.2x | – |
| Fixed Assets Turnover | 195.1x | – |
| Days Sales Outstanding | 42 days | – |
| Days Inventory | 308 days | – |
| Payables Period | 568 days | – |
| Cash Conversion Cycle | -217 days | – |
Income Statement
| Metric | CORT | SYRE |
|---|---|---|
| Total Revenue | $964M | – |
| Operating Income | $111M | -$250M |
| Net Income | $162M | -$264M |
| R&D Expense | $242M | $260M |
| SG&A Expense | $597M | – |
| Cost of Goods Sold | $14M | – |
Dividend & Shareholder Information
| Metric | CORT | SYRE |
|---|---|---|
| Shares Outstanding | 108M | 88M |
| Net Income Growth | 53.0% | – |
| EPS Growth | 70.4% | – |
CORT vs SYRE: stock comparison and AI forecast
Which is bigger, CORT or SYRE?
CORT and SYRE have similar market capitalizations ($8.86B and $8.75B).
Which one does Intratio's AI model rank higher, CORT or SYRE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.